

Remarks

Applicant has elected species of interest to it. Claims of 3-8 have been amended and claim 9 cancelled, obviating one of the species elections. The amended claims are supported in the specification *inter alia* at paragraphs 10, 12, and 13. Each of the conditions recited in claims 3-8 are taught in the specification at [13]: “Those children who have a disorder in one or more of the basic psychological processes involved in understanding or in using language, spoken or written....Such disorders include such conditions as perceptual handicaps, brain injury, minimal brain dysfunction, dyslexia, and developmental aphasia.” The amendment of the preamble of claims 1 and 2 to recite “language information processing and learning” is supported in the specification which teaches: “The invention thus provides the art with a new battery of pharmacological treatments for addressing learning, language, and other psychosocial impairments which have a neurological basis,” and “Such treatment affects the underlying neurological cause of learning, language, and psychosocial problems.” [10] and [13], respectively. These claim amendments are fully supported in the application as filed and do not add new matter to the application.

Paragraph 13 has been replaced because some of the letters in it were inadvertently cut off from the page when printed or photocopied. It is respectfully submitted that these letters do not add new matter, but rather the errors and the corrections would have been obvious to the reader of ordinary skill in the art.

Claims readable on the elected species are:

- a. cholinesterase inhibitor: claims 1-8, 10-19, and 23-40;
- b. donezepil:1-8, 10-12, and 23-40.

Respectfully submitted,

BANNER & WITCOFF, LTD.

By: \_\_\_\_\_ /Sarah A. Kagan/  
Sarah A. Kagan  
Registration No. 32,141

Date: 30 Janauary, 2008

Banner & Witcoff, Ltd.  
Customer Number: 22907